SBIR-STTR Award

Novel Caveolin Modulators as Therapeutics for Uveitis
Award last edited on: 6/9/16

Sponsored Program
SBIR
Awarding Agency
NIH : NEI
Total Award Amount
$266,284
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
David D Eveleth

Company Information

E&B Technologies LLC (AKA: E And B Technologies)

4868 Almondwood Way
San Diego, CA 92130
   (917) 628-8502
   N/A
   N/A
Location: Single
Congr. District: 52
County: San Diego

Phase I

Contract Number: 1R43EY024792-01
Start Date: 9/1/14    Completed: 8/31/15
Phase I year
2014
Phase I Amount
$208,885
Novel caveolin modulators as therapeutics for uveitis Project Summary This research proposal seeks to develop a novel therapy for uveitis based upon modulation of inflammatory signaling via caveolae. Uveitis drives 5-20% of blindness, affecting people of working age and producing significant disability in patients with chronic disease. Caveolin modulators such as cavtratin are known to be able to modulate inflammatory signaling including edema and leukocyte migration, key elements of the pathogenic cascade in uveitis. E&B Technologies is developing an improved, second generation cavtratin, CVX-001, for the treatment of uveitis. The project goal is to demonstrate that CVX-001 can prevent retinal inflammation in mouse and rabbit models of uveitis and, in phase II, IND enabling work completed. Longer term, proof of concept in human clinical testing will be pursued and the clinical trials needed for regulatory approval will be conducted. Successful completion of this project will establish a new therapeutic option for uveitis sufferers with a reduction in blindnessand visual impairment. 1

Thesaurus Terms:
Acute;Adverse Event;Affect;Age;Analog;Animal Model;Antigens;Autoimmune Encephalitis;Autoimmune Uveitis;Base;Blindness;Blood Vessels;Caveolae;Caveolins;Cells;Chronic;Chronic Disease;Clinical;Clinical Trials;Collaborations;Development;Disability;Disease;Dose;Drug Kinetics;Edema;Elements;Experimental Models;Extravasation;Generations;Genus Mycobacterium;Goals;Gold;Health Sciences;Human;Hybrid Cells;Immunomodulators;Immunosuppressive Agents;Improved;Inflammation;Inflammatory;Inflammatory Modulation;Intravitreal Injection;Killings;Laboratories;Lead;Leukocytes;Migration;Modeling;Mouse Model;Mus;Novel;Novel Therapeutics;Oregon;Oryctolagus Cuniculus;Outcome Measure;Patients;Peptides;Pharmaceutical Preparations;Phase;Prevent;Primary Outcome;Process;Public Health Relevance;Research;Research Clinical Testing;Research Proposals;Research Study;Response;Retinal;Retinal Damage;Riii Mouse;Route;Saturn's Moon Phoebe;Scaffold;Signal Transduction;Technology;Therapeutic;Toxic Effect;Toxicology;Universities;Uveitis;Vascular Permeabilities;Vision;Visual Impairment;Work;

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
$57,399